The First Clinical College, Shandong Chinese Medical University, Ji Nan, People's Republic of China.
Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji Nan, People's Republic of China.
Int J Chron Obstruct Pulmon Dis. 2022 Sep 1;17:2001-2011. doi: 10.2147/COPD.S370817. eCollection 2022.
Acute respiratory failure (ARF) is a common cause of admission to the intensive care unit (ICU) for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). There is still a lack of effective interventions and treatments. ACE inhibitors (ACEI)/ angiotensin II receptor blockers (ARB) were effective in COPD patients. We aimed to study the effect of ACEI/ARB use on AECOPD combined with ARF and evaluate the effect of in-hospital continuation of medication.
We included patients with AECOPD and ARF from the Medical Information Bank for Intensive Care (MIMIC-III) database. MIMIC III is a large cohort database from Boston, USA. Patients were divided into two groups according to the use of ACEI/ARB before admission. Propensity score matching (PSM) was used to reduce potential bias between the two groups. Cox regression and Kaplan-Meier curves compared 30-day mortality in ACEI/ARB users and non-users. We also defined and analyzed the use of in-hospital ACEI/ARB. Multiple models were used to ensure the robustness of the findings. Subgroup analysis was used to analyze the variability between groups.
A total of 544 patients were included in the original study. After PSM, 256 patients were included in the matched cohort. Multivariate Cox regression showed 30-day mortality was significantly lower in ACEI/ARB users compared with controls (HR = 0.50, 95% CI: 0.29-0.86, = 0.013). In PSM and inverse probability-weighted models, the results are stable Continued in-hospital use of ACEI/ARB remains effective (HR 0.40, 95% CI 0.22-0.74, = 0.003). Kaplan-Meier showed a significant difference in survival between the two groups.
This study found that pre-hospital ACEI/ARB use was associated with reduced mortality in patients with AECOPD and ARF.
急性呼吸衰竭(ARF)是慢性阻塞性肺疾病(COPD)急性加重患者入住重症监护病房(ICU)的常见原因。目前仍然缺乏有效的干预和治疗措施。血管紧张素转换酶抑制剂(ACEI)/血管紧张素 II 受体阻滞剂(ARB)对 COPD 患者有效。我们旨在研究 ACEI/ARB 使用对 AECOPD 合并 ARF 的影响,并评估住院期间继续用药的效果。
我们从美国波士顿的大型队列数据库 Medical Information Bank for Intensive Care(MIMIC-III)数据库中纳入 AECOPD 和 ARF 患者。患者根据入院前是否使用 ACEI/ARB 分为两组。采用倾向评分匹配(PSM)减少两组间的潜在偏倚。Cox 回归和 Kaplan-Meier 曲线比较 ACEI/ARB 使用者和非使用者 30 天死亡率。我们还定义和分析了住院期间 ACEI/ARB 的使用。采用多种模型确保结果的稳健性。进行亚组分析以分析组间的变异性。
共有 544 名患者纳入原始研究。经过 PSM,256 名患者纳入匹配队列。多变量 Cox 回归显示,ACEI/ARB 使用者与对照组相比,30 天死亡率显著降低(HR=0.50,95%CI:0.29-0.86,=0.013)。在 PSM 和逆概率加权模型中,结果均稳定。住院期间继续使用 ACEI/ARB 仍然有效(HR 0.40,95%CI 0.22-0.74,=0.003)。Kaplan-Meier 显示两组间生存存在显著差异。
本研究发现,入院前 ACEI/ARB 的使用与 AECOPD 和 ARF 患者的死亡率降低相关。